View More Recent Stories

Apr 21, 2022 07:00AM BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
Apr 19, 2022 06:00AM BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
Apr 15, 2022 06:00AM China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
Apr 11, 2022 06:00AM IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
Apr 8, 2022 07:00AM BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
Apr 6, 2022 05:00AM BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
Mar 15, 2022 08:00AM BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
Mar 11, 2022 07:00AM China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
Mar 3, 2022 07:00AM BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
Mar 1, 2022 05:30AM BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference
Feb 25, 2022 07:00AM BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 22, 2022 07:03AM BeiGene (BGNE) Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
Feb 22, 2022 07:00AM BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
Feb 22, 2022 07:00AM BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
Feb 17, 2022 05:00AM BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
Feb 1, 2022 07:00AM Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
Jan 28, 2022 05:00AM BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
Jan 24, 2022 05:00AM BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
Jan 20, 2022 05:00AM BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
Dec 20, 2021 04:00AM BeiGene Announces Launch of Bioisland Innovation Center
Dec 14, 2021 11:00PM BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
View More Recent Stories